Description

[3S-[2[R*(R*)],3R*]]-2-[2-[[1-(Ethoxycarbonyl)-3-Phenylpropyl]Amino]-1-Oxopropyl]-1,2,3,4-Tetrahydro-3-Isoquinolinecarboxylic Acid Ethyl Ester (2Z)-2-Butenedioate is a high-purity, non-peptidic renin inhibitor intermediate of significant pharmaceutical importance. This compound is critical for the research and development of antihypertensive agents, offering a key building block for advanced drug discovery programs. It is primarily utilized by pharmaceutical R&D laboratories, contract research organizations (CROs), and manufacturers of active pharmaceutical ingredients (APIs) focused on cardiovascular therapeutics.

Application

• Pharmaceutical Intermediate: Serves as a key chiral synthon in the multi-step synthesis of Aliskiren and related renin inhibitor drug candidates.
• Drug Discovery & Development: Used in medicinal chemistry for structure-activity relationship (SAR) studies and the creation of novel antihypertensive compounds.
• Reference Standard: Employed as an analytical standard for method development, validation, and quality control in API manufacturing.
• Process Chemistry Research: Utilized in route scouting, optimization, and scale-up studies for efficient production of renin inhibitors.
• Academic Research: Supports biochemical and pharmacological studies investigating the renin-angiotensin system (RAS).

Basic Information

Product Name	[3S-[2[R*(R*)],3R*]]-2-[2-[[1-(Ethoxycarbonyl)-3-Phenylpropyl]Amino]-1-Oxopropyl]-1,2,3,4-Tetrahydro-3-Isoquinolinecarboxylic Acid Ethyl Ester (2Z)-2-Butenedioate
CAS No.	103733-36-4
Molecular Formula	C31H38N2O8
Molecular Weight	566.65 g/mol
Synonyms	Aliskiren Intermediate; (2Z)-2-Butenedioic acid compd. with ethyl (3S,5S,8S,9S,11S,14S,16S)-14-(ethoxycarbonyl)-5,16-dimethyl-8-[(2-methylpropyl)formamido]-2,15-dioxo-3-(phenylmethyl)-1,4,7,10,13,16-hexahazacyclohexadec-11-ancarboxylate (1:1); SPP-100 Intermediate; CGP-60536B; Ethyl (2S,4S,5S)-5-[(N-{2-methylpropyl)-N-[(2S)-2-[[(2S,3R)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]amino]-4-hydroxy-2-phenylpentanoate fumarate; Renin Inhibitor Intermediate.
EINECS	Contact for details

Quality Control

Our production of this advanced pharmaceutical intermediate adheres to stringent GMP (Good Manufacturing Practice) guidelines to ensure batch-to-batch consistency and traceability. Every lot undergoes comprehensive analytical characterization, including HPLC for purity and chiral purity, to meet exacting research and development specifications. A detailed Certificate of Analysis (COA) is provided with each shipment, documenting identity, assay, impurity profile, and other critical quality attributes.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at a controlled room temperature (15-25°C). This compound is hygroscopic (moisture-sensitive); the container must be kept tightly sealed in a dry environment to prevent degradation.

Specification

Item	Specification
Appearance	White to off-white crystalline powder
Identification (IR)	Conforms to structure
Identification (HPLC)	Retention time matches reference standard
Assay (HPLC)	≥ 98.0%
Chiral Purity (Chiral HPLC)	≥ 99.0% ee
Water Content (KF)	≤ 0.5%
Residue on Ignition	≤ 0.1%
Heavy Metals	≤ 10 ppm
Related Substances (HPLC)	Total impurities ≤ 1.0%; Any single impurity ≤ 0.5%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.